Onconetix, Inc. (ONCO)
- Previous Close
4.6000 - Open
4.3900 - Bid 4.3000 x 100
- Ask 4.6000 x 100
- Day's Range
4.2700 - 4.6500 - 52 Week Range
2.8000 - 21.4000 - Volume
87,626 - Avg. Volume
853,058 - Market Cap (intraday)
37.324M - Beta (5Y Monthly) 3.66
- PE Ratio (TTM)
-- - EPS (TTM)
-109.2000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
onconetix.gcs-web.comRecent News: ONCO
View More
Performance Overview: ONCO
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCO
View MoreValuation Measures
Market Cap
37.32M
Enterprise Value
51.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.56
Price/Book (mrq)
--
Enterprise Value/Revenue
35.30
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.85%
Return on Equity (ttm)
--
Revenue (ttm)
1.46M
Net Income Avi to Common (ttm)
-53.12M
Diluted EPS (ttm)
-109.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
930.54k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.06M
Research Analysis: ONCO
View MoreCompany Insights: ONCO
ONCO does not have Company Insights